Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2,563

A new patent granted to Apple details how the company is thinking of using the Vision Pro’s external display to show what the wearer is looking at inside the device.

The patent, which includes Jony Ive as an inventor, details ways an outside screen on a generic head-mounted display could be used to indicate what the wearer is seeing to people around them. While the patent isn’t specifically about the Vision Pro and its “EyeSight” display feature, it’s clear that some of the ideas here informed the features in the final headset.

For example, Apple has talked publicly about how the outer screen on the Vision Pro can let outsiders see the eyes of the person wearing the headset or display a colorful pattern that indicates the wearer is fully immersed in VR. But pictures in the patent detail how an external display could be used for a few sillier-looking applications, like displaying the weather, sunglasses on your face, a DO NOT DISTURB sign, or even replacing the wearer’s eyes with Zoom icons.

Read more | >

Qualcomm extends its presence in AI inference processing, began with its Cloud AI 100 series accelerators, with the launch of its new Qualcomm Cloud AI 100 Ultra.

While Qualcomm’s Cloud AI 100 accelerator family has long been available from several tier-one technology providers such as Lenovo, Hewlett Packard Enterprise (HPE), Inventec, Foxconn, Gigabyte, and Asus, it’s starting to see deployment in the public cloud.

Amazon Web Services (AWS) recently introduced its first Qualcomm-based accelerated instance type, the DL2q, featuring the Qualcomm Cloud AI 100. While the new instance type can be used for general inference applications, the companies highlight the accelerator’s specific applicability in developing automotive ADAS and related applications – an area in which Qualcomm is rapidly expanding its presence.

Read more | >

Breast cancer is the most frequently diagnosed cancer and accounts for 12.5% of all new cancer cases globally. And while the overall incidence has been decreasing and five-year survival rates in the U.S. exceed 90%, the burden of this disease cannot be underestimated.

On December 20, a new study titled “ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer” was published in the Proceedings of the National Academy of Sciences by a team of Stanford researchers led by Lingyin Li, one of the top experts in the STING pathway in cancer.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) is a multifaceted enzyme that plays a significant role in various biological processes. At its core, ENPP1 is known for its ability to break down ATP, a primary energy molecule in the body, into AMP and inorganic pyrophosphate. This activity is crucial in regulating bone mineralization and preventing abnormal calcium deposits in the body. In addition to its role in bone health, ENPP1 is also involved in regulating insulin signaling, which links it to metabolic disorders like diabetes.

Read more | >

A new paper published in Frontiers in Psychology: Performance Science led by Andy Parra-Martinez at the University of Arkansas “describes the general status, trends, and evolution of research on talent identification across multiple fields globally over the last 80 years,” by drawing from the Scopus and Web of Science databases and conducting a bibliometric analysis of 2,502 documents.

Bibliometric analysis is a way of understanding the structure and citation patterns of research around a given topic, in this case, talent identification research.

Talent identification research is concentrated in business, sports, and education

Talent identification (TI) research is “concentrated in the fields of management, business, and leadership (~37%), sports and sports science (~20%), and education, psychology, and STEM (~23%). Whereas research in management and sports science has occurred independently, research in psychology and education has created a bridge for the pollination of ideas across fields.”

Read more | >